- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
**Financial Highlights:**
Rossari Biotech has shown impressive financial results for Q4 FY25, registering a revenue of Rs. 579.6 crore, reflecting a year-on-year increase of 22.6%. The EBITDA stood at Rs. 69.5 crore, with a margin of 12.0%. Annual revenue reached Rs. 2,080.3 crore, a 13.6% growth over FY24, while the profit after tax (PAT) increased by 4.4% to Rs. 136.4 crore. Although EBITDA margins saw a decline of 90 bps to 12.7% for the full year, overall results indicate steady performance amid a soft operating environment.
**Strategic Initiatives and Growth Drivers:**
The company is expanding capacity with significant capex plans amounting to Rs. 192 crore across its subsidiaries. New projects aim to enhance manufacturing capabilities and address rising demand in key sectors, including health and hygiene.
**Business Developments:**
Rossari's exports continued to thrive, reaching over 70 countries, validating its strategic investments in global partnerships. The management remains optimistic about growth prospects in emerging verticals such as institutional cleaning and B2C products.
**Market Position and Competitive Advantage:**
Rossari has reinforced its market presence as a leader in specialty chemicals, benefiting from a diversified product portfolio and an expanding distribution network.
**Investor Implications:**
With a strong balance sheet and ongoing investments, Rossari is poised for sustainable growth. The recent dividend announcement of Rs. 0.50 per share further underscores the company’s commitment to delivering value to shareholders. Investors should remain confident in Rossari’s ability to navigate market challenges and capitalize on new opportunities.